(Q37926477)

25 August 2017

1 reference

title

Molecular mechanisms of cisplatin resistance (English)

1 reference

25 August 2017

1 reference

2

L Senovilla

0 references

Guido Kroemer

8

G Kroemer

0 references

Lorenzo Galluzzi

1

L Galluzzi

0 references

Oliver Kepp

6

O Kepp

0 references

Isabelle Martins

5

I Martins

0 references

Ilio Vitale

3

I Vitale

0 references

Maria Castedo

7

M Castedo

1 reference

25 August 2017

I Vitale

3

1 reference

25 August 2017

J Michels

4

1 reference

25 August 2017

language of work or name

English

0 references

publication date

5 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

31

1 reference

25 August 2017

issue

15

1 reference

25 August 2017

page(s)

1869-1883

1 reference

ERCC1-XPF endonuclease facilitates DNA double-strand break repair

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase eta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Survivin, cancer networks and pathway-directed drug discovery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Post-translational modifications and activation of p53 by genotoxic stresses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

A family of drug transporters: the multidrug resistance-associated proteins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Apoptosis regulation in tetraploid cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

DNA repair: enzymatic mechanisms and relevance to drug response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Satraplatin: an orally available platinum analog for the treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

EGF-ERBB signalling: towards the systems level

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Cisplatin: from DNA damage to cancer chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Overexpression of N-methylpurine-DNA glycosylase in Chinese hamster ovary cells renders them more sensitive to the production of chromosomal aberrations by methylating agents--a case of imbalanced DNA repair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Cisplatinum and taxol induce different patterns of p53 phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Resistance to therapy caused by intragenic deletion in BRCA2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Mcl-1, Vascular Endothelial Growth Factor-R2, and 14-3-3 Expression Might Predict Primary Response against Radiotherapy and Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinomas of the Head and Neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Medical treatment of advanced testicular cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

31 March 2020

Mirk/Dyrk1B in cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Recent developments in the field of anticancer platinum complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Mitochondrial liaisons of p53.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Clinical perspectives on platinum resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Molecular mechanisms of mammalian global genome nucleotide excision repair.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Is cisplatin-induced cell death always produced by apoptosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carc

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Preclinical studies identifying carboplatin as a viable cisplatin alternative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

The internalization and degradation of human copper transporter 1 following cisplatin exposure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

The ATP-dependent glutathione S-conjugate export pump

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

The resurgence of platinum-based cancer chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Preclinical perspectives on platinum resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Overexpression of metallothionein confers resistance to anticancer drugs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Tumor-suppressor p53: implications for tumor development and prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Mitochondrial membrane permeabilization in cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Autophagy and the Integrated Stress Response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Reversal of multidrug resitance by natural substances from plants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Role of the copper transporter, CTR1, in platinum-induced ototoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

BRCA1 and BRCA2: 1994 and beyond

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Calreticulin exposure dictates the immunogenicity of cancer cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Ovarian cancer: new clinical approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Cisplatin (cis-diamminedichloroplatinum II)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Survivin: a new target for anti-cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

The role of copper transporters in the development of resistance to Pt drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Mutagenic and carcinogenic properties of platinum-based anticancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

A cyclopalladated complex interacts with mitochondrial membrane thiol-groups and induces the apoptotic intrinsic pathway in murine and cisplatin-resistant human tumor cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Cisplatin: mode of cytotoxic action and molecular basis of resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Nitrone spin traps and a nitroxide antioxidant inhibit a common pathway of thymocyte apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Immunogenic death of colon cancer cells treated with oxaliplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Cancer susceptibility and the functions of BRCA1 and BRCA2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Mitotic catastrophe: a mechanism for avoiding genomic instability.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

p53 in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Caspase-mediated cleavage of ATM during cisplatin-induced tubular cell apoptosis: inactivation of its kinase activity toward p53.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Requirement for ERK activation in cisplatin-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Loss of DNA polymerase zeta causes chromosomal instability in mammalian cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

DNA damage recognition and nucleotide excision repair in mammalian cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

c-Abl phosphorylation of ΔNp63α is critical for cell viability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.384

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.384

1 reference

Dimensions Publication ID

25 August 2017

1008798576

0 references

1 reference